相关临床试验
13
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1981
已完成
6
46.1%
Enrolling By Invitation
1
7.7%
招募中
4
30.8%
终止
1
7.7%
Unknown
1
7.7%
暂无批准数据
- Sutter's CPMC Van Ness Campus performed its first TULSA-PRO procedure on Aug. 6, offering MRI-guided transurethral ultrasound ablation for prostate cancer and BPH. - SSM Health Saint Louis University Hospital has become a regional leader in the Midwest for TULSA-PRO, an incision-free focal therapy for localized prostate cancer. - Urologists report the targeted approach reduces risks of urinary incontinence and sexual dysfunction compared with traditional surgery and radiation. - Patients describe preserved quality of life and minimal recovery burden, with one reporting resolution of minor urinary issues six months after treatment.
- The FDA authorized Vitestro's Aletta, the first standalone robotic device that draws blood from a patient's arm without hands-on operator intervention. - Aletta uses near-infrared light, Doppler ultrasound, robotics, and AI to locate veins, insert the needle, and complete the blood draw autonomously. - One phlebotomist can oversee up to three Aletta devices, which may help address the growing shortage of trained phlebotomists in the U.S. - Clinical data showed successful blood draw rates comparable to or better than trained human phlebotomists, with device-related adverse events uncommon and mild.
- Vitestro raised $70 million in Series B funding to prepare its autonomous diagnostic blood collection robot Aletta for US market launch via FDA's de novo pathway. - The Aletta device combines near-infrared imaging, ultrasound, and artificial intelligence to identify veins and automate the entire blood collection process from tourniquet application to bandage placement. - Clinical data demonstrates that Aletta achieves first-time blood draw success rates and procedure durations comparable to manual phlebotomy, while maintaining similar hemolysis rates. - The funding round was backed by notable healthcare investors including Labcorp Venture Fund, Mayo Clinic, and Sutter Health, supporting the company's expansion from its current European operations.
- C. Light Technologies has been selected as one of five projects funded through the Roche MS Innovation Challenge to develop eye movement biomarkers for multiple sclerosis progression detection. - The company will launch a two-year clinical trial with UCSF and Sutter Health using their FDA-cleared Retitrack technology to identify fixational eye movements as non-invasive biomarkers for MS progression. - The study aims to determine if microscopic eye movement changes can predict progression independent of relapse activity (PIRA) earlier than current standard measures like EDSS and MRI. - C. Light received a new CPT code from the American Medical Association for retinal eye tracking, which becomes effective January 1, 2026, opening potential insurance reimbursement pathways.
- Abridge raised $300 million in Series E funding led by Andreessen Horowitz, bringing its valuation to $5.3 billion for its ambient listening technology that automates clinical documentation. - The AI-powered platform serves over 150 health systems including Kaiser Permanente, UPMC, and Sutter Health, generating clinical notes from medical conversations across 55 specialties and 28 languages. - The company reports significant clinical impact with 60-70% reduction in burnout and over 90% clinician retention rate, while projecting support for more than 50 million medical conversations in 2025. - This funding round follows a $250 million raise in February, representing one of the most substantial health tech deals of 2024 as AI scribes gain rapid adoption to address clinician burnout.
- Leading cancer centers demonstrate pharmacists' expanding roles in direct patient care, including running therapeutic clinics, managing treatment protocols, and interpreting pharmacogenomic test results. - Pharmacists are increasingly involved in clinical trials management, improving patient enrollment through medication reconciliation and coordination with other healthcare providers. - Despite proven value in oncology care delivery, pharmacists face ongoing challenges in achieving federal recognition as providers, limiting reimbursement opportunities and resource allocation.
